Clinical trials: Normal Responders
Rheumatoid Arthritis
Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis
This study was intended to evaluate the safety and efficacy of intravenous (IV) ACZ885 and oral methotrexate (MTX) therapy in patients with early rheumatoid arthritis (RA)
- Trial name
- NCT00487825
- Testing
- Canakinumab (investigational), Methotrexate (MTX)
- Where
- 22 sites in United States, Belgium and 4 more
- Volunteers
- 78 people
- Sponsor
- Novartis
Heart Failure
Cardiac MR (CMR) in Cardiac Resynchronization Therapy Non-responders
Cardiac MR (CMR) will be used to assess myocardial activation and hemodynamics in patients with CRT. Goals are to demonstrate that differences in Left ventricle (LV)- right ventricle (RV) pacing delays cause differences in…
- Trial name
- NCT01367691
- Testing
- CRT reprogramming (Medtronic CRT)
- Where
- Germany
- Volunteers
- 1 people
- Sponsor
- University Hospital, Bonn
Androgen Receptor Gene Overexpression, Normal Responders
Androgen Receptor mRNA Expression is Positively Associated With Live Birth in Women Undergoing IVF Independently of the Type of Ovarian Response
AR is a steroid hormone receptor that regulates various genes' expression and affects cellular proliferation and differentiation.
- Conditions
- Androgen Receptor Gene Overexpression, Normal Responders, Poor Ovarian Response, Bologna Criteria
- Trial name
- NCT03433768
- Testing
- Real time PCR
- Volunteers
- 67 people
- Sponsor
- Aristotle University Of Thessaloniki
Rheumatoid Arthritis
Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis (RA) Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW)
The purpose of this study objective will be to evaluate the efficacy and safety of etanercept 50 mg BIW in RA subjects who showed a sub-optimal response to standard dose etanercept (50 mg QW) and concomitant methotrexate therapy.
- Trial name
- NCT00115219
- Testing
- Etanercept
- Volunteers
- 200 people
- Sponsor
- Amgen
Alopecia Areata
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of alopecia areata.
- Trial name
- ALLEGRO-100 (NCT06873945)
- Testing
- Ritlecitinib 100 mg, Ritlecitinib 50 mg
- Where
- 148 sites in United States, Canada and 9 more
- Volunteers
- 674 people
- Sponsor
- Pfizer
Psoriasis
Etanercept With Tacrolimus for Psoriasis
The study is designed to evaluate the efficacy of etanercept 50 mg subcutaneously (SQ) weekly plus tacrolimus 0.1% topical ointment twice daily compared to etanercept 50 mg SQ weekly plus placebo ointment twice daily.
- Trial name
- NCT00134394
- Testing
- Etanercept plus tacrolimus
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Rheumatoid Arthritis
Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Participants
The primary objective of the study was to evaluate the long-term safety and tolerability of filgotinib (formerly GLPG0634) for the treatment of rheumatoid arthritis.
- Trial name
- DARWIN3 (NCT02065700)
- Testing
- Filgotinib
- Where
- 111 sites in United States, Argentina and 20 more
- Volunteers
- 739 people
- Sponsor
- Lakefront Biotherapeutics NV
Rheumatoid Arthritis
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis
The purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-986454 in participants with Rheumatoid Arthritis
- Trial name
- NCT07171983
- Testing
- BMS-986454
- Where
- 9 sites in India
- Volunteers
- 46 people
- Sponsor
- Bristol-Myers Squibb
Arthritis, Rheumatoid
Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders
Rheumatoid arthritis (RA) is the most common inflammatory rheumatoid disease in France, affecting 0.3% of the general population.
- Trial name
- SUNSTAR (NCT03227419)
- Testing
- Tocilizumab Prefilled Syringe, Abatacept Prefilled Syringe
- Where
- 26 sites in France
- Volunteers
- 224 people
- Sponsor
- Lille Catholic University
Infertility
Follicular Activation in Poor Responders
This study aims to assess whether activation of primordial follicles through ovarian cortex fragmentation may increase the number of antral follicles present in the ovary of patients with diminished ovarian reserve.
- Trial name
- FAPPOR (NCT02354963)
- Testing
- In vitro fragmentation of the ovarian tissue
- Where
- Spain
- Volunteers
- 34 people
- Sponsor
- César Díaz García
Rheumatoid Arthritis
Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients
Ninety patients suffering from active rheumatoid arthritis despite continued treatment with methotrexate will be evaluated for improvement of disease activity when taking GLPG0634 (4 different doses will be evaluated) or matching…
- Trial name
- NCT01668641
- Testing
- GLPG0634
- Where
- 19 sites in Hungary, Moldova and 2 more
- Volunteers
- 91 people
- Sponsor
- Lakefront Biotherapeutics NV
Breast Adenocarcinoma
Assessing Combined SBRT in Breast Cancer Non-Responders to Neoadjuvant Chemotherapy
The goal of this clinical trial is to assess whether the addition of preoperative stereotactic body radiation therapy (SBRT) can improve pathological complete response (pCR) rates and safety in breast cancer patients who do not…
- Trial name
- NCT06596018
- Testing
- SBRT, Chemotherapy
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Estrogen Receptor Negative, HER2 Positive Breast Carcinoma
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
This clinical trial studies eliminating surgery and/or radiation therapy in treating breast cancer patients. In HER2 positive and triple negative breast cancers, after systemic therapy, when image-guided biopsy shows no residual…
- Conditions
- Estrogen Receptor Negative, HER2 Positive Breast Carcinoma, HER2/Neu Negative, Invasive Breast Carcinoma
- Trial name
- NCT02945579
- Testing
- Undergo EBRT, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- 8 sites in United States
- Volunteers
- 120 people
- Sponsor
- M.D. Anderson Cancer Center
Female Pattern Hair Loss, Androgenetic Alopecia
Minoxidil Dose Response Study in Females Identified Through IVD Testing as Non-Responders to 5% Topical Minoxidil
5% topical minoxidil is the maximum dosage approved by the US FDA for the treatment of female pattern hair loss. While topical minoxidil exhibits a good safety profile, the efficacy in the overall population is relatively low…
- Trial name
- NCT02486848
- Testing
- 5% Topical Minoxidil Solution, 15% Topical Minoxidil Solution
- Where
- Italy
- Sponsor
- Maja Kovacevic, MD
Rheumatoid Arthritis
Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)
Participants suffering from active rheumatoid arthritis despite continued treatment with methotrexate were evaluated for improvement of disease activity (efficacy) when taking GLPG0634 (3 different doses - 50 milligram [mg], 100…
- Trial name
- DARWIN1 (NCT01888874)
- Testing
- GLPG0634
- Where
- 142 sites in United States, Argentina and 20 more
- Volunteers
- 599 people
- Sponsor
- Lakefront Biotherapeutics NV
Atopic Dermatitis
An Observational Study of Upadacitinib to Assess Change in Disease Activity in Canadian Adult Participants With Moderate-to-Severe Atopic Dermatitis Who Are Inadequate Responders To or Discontinuing Dupilumab
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic…
- Trial name
- CAN UpTIMISE (NCT05394792)
- Where
- 25 sites in Canada
- Volunteers
- 111 people
- Sponsor
- AbbVie
Breast Cancer, Invasive Breast Cancer
A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer
The purpose of this study to test an alternative treatment approach that involves giving participants radiotherapy before their mastectomy (preoperative radiotherapy) and performing immediate reconstruction surgery at the time of…
- Trial name
- NCT05412225
- Testing
- Pre-neoadjuvant radiotherapy (NART) biopsy, Neoadjuvant radiotherapy, Unilateral total mastectomy with axillary lymph node dissection
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer, Breast Cancer
Genomic Investigation of Unusual Responders
Studies have shown that tumors from the same patient may respond very differently to the same therapeutic agents. This study aims to investigate the genetic basis of tumors that respond abnormally well or poorly to therapeutic…
- Conditions
- Cancer, Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer
- Trial name
- GENIUS (NCT03740503)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University Health Network, Toronto
Arthritis, Rheumatoid
Efficacy and Safety of CDP870 and Methotrexate Compared to Methotrexate Alone in Subjects With Rheumatoid Arthritis
The main purpose of the study was to determine the efficacy of CDP870 in treating RA signs/symptoms in patients who were partial responders to MTX.
- Trial name
- NCT00544154
- Testing
- CDP870
- Volunteers
- 247 people
- Sponsor
- UCB Pharma
Rheumatoid Arthritis
Rituximab (RTX) for Disease Modifying Anti Rheumatic Drug (DMARD) Non-responders in Pakistan: The Pakistan Rituximab Study (PARIS)
A study to determine the efficacy and safety of rituximab in Pakistani patients with rheumatoid arthritis (RA) who have been inadequately controlled with standard disease modifying anti rheumatic drugs (DMARDs).
- Trial name
- PARIS (NCT02731560)
- Testing
- Rituximab
- Volunteers
- 74 people
- Sponsor
- Prof. Abid Z. Farooqi